Leaked FDA memo flags 10 child death reports after COVID vaccination

A confidential memo written by a senior U.S. Food and Drug Administration (FDA) official has reignited debate over the safety profile of COVID-19 vaccines in children, after an internal review suggested that at least ten pediatric deaths might be linked to post-vaccination myocarditis. The memo, authored by FDA Chief Medical and Scientific Officer Dr. Vinay Prasad, reviewed 96 child death reports submitted between 2021 and 2024 to national vaccine surveillance systems. According to his assessment, ten of these deaths appear plausibly connected to COVID-19 vaccination, with myocarditis heart muscle inflammation emerging as the most likely cause. Dr. Prasad described the finding as “profound,” noting that this is the first time the FDA has internally acknowledged that COVID-19 vaccines may have caused the deaths of American children between the ages of seven and sixteen. He also suggested that the real number could be higher due to underreporting.

The memo remained unknown to the public until Reuters (News agency) obtained and reported it, bringing the issue into sharp focus at a politically sensitive moment. Its emergence coincides with a significant policy shift by the new U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a long-time critic of vaccine policies, who recently limited COVID-19 vaccine recommendations only to adults aged 65 and above and individuals with serious health conditions. This unexpected reversal from earlier administrations has heightened the impact of the memo’s contents, as it appears to reinforce the shift toward more restrictive vaccine guidance. The leak also comes as the FDA is weighing major regulatory reforms, including mandatory randomized clinical trials for new vaccine approvals, the reevaluation of annual flu-shot selection processes, stronger safety data requirements for pregnancy vaccinations, and tighter post-market surveillance. Dr. Prasad’s findings appear to bolster arguments for stricter oversight, intensifying internal debates within the agency.

The memo also contradicts years of public messaging from U.S. health authorities, who consistently stated that no child deaths had been causally linked to COVID-19 vaccination. An internal acknowledgment of possible fatal cases has therefore raised serious questions about transparency, risk communication, and accountability. The issue has drawn added attention because it involves myocarditis a side effect that has been extensively studied and debated, particularly among adolescent males following mRNA vaccination. Although vaccine-associated myocarditis remains rare and is generally mild, the new suggestion of potential fatal cases has intensified scrutiny.

Experts caution that the internal review relies in part on reports from the Vaccine Adverse Event Reporting System (VAERS), a passive reporting system that does not establish causation on its own. VAERS entries require validation through more rigorous analyses, clinical records, and autopsy data. Several medical specialists have urged the FDA to release the full internal analysis to enable independent assessment. Others stress that COVID-19 infection itself carries a higher risk of myocarditis than vaccination, suggesting that risk-benefit evaluations must be interpreted in the correct scientific context. Despite differing views, there is broad agreement that greater transparency is essential.

Politically, the leaked memo is expected to strengthen calls for reassessing pediatric COVID-19 vaccination and may influence school immunization policies, public trust in health institutions, and the future regulatory landscape for mRNA vaccines. Critics of the new restrictive approach warn that excessive caution could slow vaccine innovation and weaken preparedness for future outbreaks. Meanwhile, members of Congress are likely to question FDA leadership about the internal findings, decision-making processes, and communication strategies used during the pandemic years.

In sum, the leaked memo has brought the question of vaccine safety for children back to the forefront, not solely because of the findings themselves but because of its timing: a sweeping shift in national vaccine policy, internal FDA debates over regulatory reforms, and ongoing public concern about myocarditis. While the memo suggests ten child deaths may be vaccine-related, experts insist that full transparency and further analysis are needed. What is clear is that this revelation has triggered one of the most consequential discussions about vaccine oversight since COVID-19 vaccines were first introduced.